AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06000787 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: External beam radiotherapy
Description: Subjects with diffuse midline glioma on PNOC023 (NCT04732065) Arm A or B receive standard-of-care external beam radiotherapy to the brain tumor.
Study NCT05412875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05412875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06204978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: short-chain fructo-oligosaccharides (dose 1)
Description: 10 g / day at breakfast during 7 days (Day 8 - Day 14)
Study NCT06204978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: short-chain fructo-oligosaccharides (dose 2)
Description: 20 g / day at breakfast during 7 days (Day 8 - Day 14)
Study NCT06204978 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Baseline
Description: 0 g / day of short-chain fructo-oligosaccharides during 7 days (Day 1 - Day 7)
Study NCT05135624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP16 (12 mg)
Description: SP16 will be administered as a single 2 mL s.c. injection of 3 mg/mL SP16 and 1 concurrent separate 2 mL s.c. injection of sterile water
Study NCT06214416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstention
Description: All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote abstention.
Study NCT06214416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean alcohol-drinking pattern
Description: All the intervention will be carried out online once a month for a year, focusing on nutritional, behavioral and scientific evidence aspects, that promote the Mediterranean alcohol-drinking pattern.
Study NCT05015439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: The study intervention will be supplied as a softgel capsule containing cannabidiol.
Study NCT05015439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study intervention will be supplied as a softgel capsule containing inert filler.
Study NCT06215807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser arcuate keratotomy
Description: The patient will receive femtosecond laser arcuate keratotomy and femtosecond laser-assisted cataract surgery with implantation of a monofocal intraocular lens in one eye.
Study NCT06215807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toric intraocular lens implantation
Description: The patient will receive femtosecond laser-assisted cataract surgery with implantation of a Toric monofocal intraocular lens in the contralateral eye.
Study NCT05932966 — intervention group
Intervention type: DEVICE
Intervention: Insulin closed-loop delivery system
Description: Insulin closed-loop delivery system
Study NCT05232045 — intervention group
Intervention type: DRUG
Intervention: Automated urinary output collection system group (tight monitoring of urine output)
Description: Automated urinary output collection system group (tight monitoring of urine output)
Study NCT05565131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided placement with PYTHEAS® ODYSSEE
Description: Pre-surgery, the surgeon generates a 3D model of the spine from a preoperative CT scan During the perforation and insertion of the implant, the system indicates the orientation of the pedicle path and the current orientation of the instruments (perforation tool) with the orientation sensor (inertial sensor). The system also displays the position of the entry point of the planned pedicle path on the views.
Study NCT04687384 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted colectomy
Description: Robotic-assisted colectomy performed by usage of da Vinci Xi robotic technology
Study NCT04687384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic colectomy
Description: Conventional laparoscopic colectomy
Study NCT06255184 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sernity intervention
Description: Serenity Therapy is a holistic intervention that boosts psychological well-being and emotional balance through relaxation techniques, mindfulness, and guided imagery
Study NCT05657925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron 8 mg
Description: Ondansetron 8 mg prn sublingually when awakening with nausea. as per the FDA label for ondansetron.
Study NCT05657925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo will be identical in appearance to the active treatment pill
Study NCT06000787 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 131I-Metaiodobenzylguanidine (MIBG)
Description: Subjects with high-risk neuroblastoma on COG ANBL1531 (NCT03126916) Arm B receive the radiopharmaceutical 131I-Metaiodobenzylguanidine (MIBG) 15 mCi/kg via either a central or a peripheral IV catheter over 1.5 to 2 hours at a maximum rate of 500 mCi/hour.
Study NCT05504473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEURO-BLINK Device
Description: The NEURO-BLINK is a class IIa medical device that intends to restore the blink function in patients with facial palsy through the application of transcutaneous electrical stimulation.
Study NCT05688449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: A 20 ml bolus of 2 mcg/ml fentanyl + 0.125% bupivacaine solution will be administered to the bupivacaine group via the epidural catheter, and 5ml/hour infusion will be started.
Study NCT05043961 — intervention group
Intervention type: PROCEDURE
Intervention: Palisade sacroiliac joint radiofrequency ablation using 3-tined needles
Description: Palisade-RF is performed using a conventional temperature-controlled RF generator generating monopolar and bipolar lesions at 85°C for 150 sec, with a 60 sec ramp time. Four, 18 Gauge 3-tined, 90 mm cannulas with an active tip of 10 mm (RF Trident; Diros Technology) will be used along with a four-output radiofrequency generator configured for quadripolar and bipolar output.~The RF energy is delivered, making one quadripolar or two bipolar lesions at a time. This procedure is repeated at the remaining target sites by leapfroging the needles, until the entire length is lesioned.~Lesioning the L5 dorsal ramus:~o The RF needle is inserted at the inflexion between the ala of the sacrum and the S1 superior articular process. The RF energy is delivered, creating a monopolar lesion.
Study NCT05688449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: A 20 ml bolus of saline will be administered to the saline group via the epidural catheter, and 5ml/hour infusion will be started.
Study NCT06205069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue flossing
Description: While the participant will stand and perform a slight knee flexion, the band will be rolled upwards from the tibial tuberosity to 5 cm above the femoral epicondyle. The patella will not be covered. Pressure will be produced by rolling the joint with 50% tension and 50% overlap.
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: Calcium channel blocker
Description: Drugs with ATC code C08 will be categorised as calcium channel blockers.
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: Beta blocker
Description: Drugs with ATC code C07 will be categorised as beta-blockers.
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: Diuretic
Description: Drugs with ATC code C03 will be categorised as diuretics.
Study NCT05153772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlphaMedix
Description: 212Pb-DOTAMTATE is a radiolabeled derivative of octreotide targeting somatostatin positive neuroendocrine tumors
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: RAS
Description: Drugs with ATC code C09 will be categorised as RAS (agents acting on the renin angiotensin system).
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: Other AHT
Description: Drugs with ATC code C02 will be categorised as other antihypertensives.
Study NCT05143450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Pressure
Description: In the experimental group manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher before the procedure. Manual pressure reduces pain within the framework of the gate control theory. According to the gate control theory, when pressure is applied to an area, a fiber transmits the feeling of pressure instead of pain and ultimately the pain sensation is alleviated.
Study NCT04806503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UNR844
Description: Ophthalmic solution for topical ocular administration
Study NCT04806503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06199778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: 1. Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~2. Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~3. Others: Regular turning, back patting, and position changes performed by caregivers.
Study NCT05846334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindfulHeart
Description: 'mindfulHeart' is an interactive, self-guided and patient-oriented mHealth intervention for the reduction of stress in patients with IHD and includes automated feedback via visualization of changes in patient reported outcome measures (PROMs).
Study NCT05617599 — intervention group
Intervention type: DEVICE
Intervention: SUPRAFLEX CRUZ
Description: Patients in whom treatment with SUPRAFLEX CRUZ has been attempted
Study NCT04567238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile contingency management
Description: Mobile contingency management is a mobile-phone based behavioral therapy that provides positive reinforcement (i.e., money) for abstinence that is highly effective at reducing substance use.
Study NCT06214637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melissa
Description: The test solutions will be administered once a day through administration in drops for children between 5 and 10 years old and for adolescents between 11 and 16 years old. As participants will be between 5 and 16 years old, children will be given a minimum of 5 and a maximum of 10 drops of the solutions per individual (Tavares-Silva, Holandino et al. 2019) as well as a maximum of 10 drops for adolescents of solutions per individual (Taylor, Lancaster et al. 2000). Highlighting that the prescription of Melissa officinalis will be at night, around 20/30 minutes before bedtime, respecting the indications for the medications described in the Hahnemannian Materia Medica (Vijnovsky, 2003). All medications must be taken away from meals and they will be instructed not to use mentholated substances, respecting a minimum time of 30 minutes.
Study NCT06214637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
Study NCT06210945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg CM-101
Description: 10 mg/kg CM-101
Study NCT06210945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05972785 — intervention group
Intervention type: DRUG
Intervention: None AHT
Description: None AHT
Study NCT06324461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75mg subcutaneous injection
Description: Subject randomized into treatment group will receive single subcutaneous dose of Dulaglutide 0.75mg 7 to 14 days prior to surgery
Study NCT04994613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory adaptive environment
Description: A dedicated, private room that is set up in accordance with the patient's coping plan and individual needs regarding sound, light, activity level, and other stimuli.
Study NCT05309291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: Dialysis performed in HD mode.
Study NCT05309291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX 800 Dialyzer
Description: Dialysis performed in HDF mode.
Study NCT06644599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wireless monitoring
Description: The monitoring wireless system will continuously monitor the heart rate, oxygen saturation (SpO2), respiratory rate, and blood pressure and in selected patients electrocardiography (ECG).
Study NCT06512558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Additional MRI with gadolinium injection and 3D camera imaging
Description: The study includes an additional MRI with gadolinium injection, performed in addition to standard practice. In addition, 3D camera images will be acquired at the time of surgery.
Study NCT05019079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: In the electroacupuncture group, acupoints of Lieque (+), Chize (-), Sanyinjiao (-), Zusanli (+), Tanzhong (+) and Yutang (-) will be selected for electrical stimulation. Density wave will be selected, and the current intensity should be tolerated by the patients. Conventional anesthesia operation could be started after the connection of electroacupuncture, and acupuncture point stimulation will be stopped 30min later.
Study NCT06589128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin Oral Capsule
Description: Once daily supplementation of oral astaxanthin capsule for 24 weeks
Study NCT06589128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily supplementation of olive oil capsule for 24 weeks
Study NCT04950439 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collect blood sample
Description: A blood sample dedicated to the study and necessary for routine care is taken. The pulse wave velocity and systolic pressure index are measured. A myocardial CT scan coupled with a computed tomography is performed. The patient collects stools at his home, simply conditions them and sends them by mail to the centre, which stores them.
Study NCT06675292 — intervention group
Intervention type: OTHER
Intervention: Survey-based study
Description: The demographic information of individuals with tension-type headaches, along with data from the Visual Analog Scale, Migraine Disability Assessment Questionnaire, Headache Impact Test-6, Henry Ford Hospital Headache Disability Inventory, and Headache Needs Assessment, will be collected and analyzed.
Study NCT05274919 — intervention group
Intervention type: DEVICE
Intervention: Philips Achieva 7T MRI
Description: Regular follow-up MRI on 3T scanner and optional additional scan at 7T MRI.
Study NCT05274919 — intervention group
Intervention type: DEVICE
Intervention: X-ray (optional)
Description: Optional X-ray scan to assess the safety for undergoing an MR examination.
Study NCT05896839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05896839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05896839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05896839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT05274919 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Additional contrast injection
Description: Contrast agent administration for the additional 7T scan (optional).
Study NCT05274919 — intervention group
Intervention type: OTHER
Intervention: Question list
Description: Questionnaire for contra-indications for an MR examination.
Study NCT06673498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lusutrombopag combined with recombinant human thrombopoietin
Description: After eligibility is confirmed, patients will begin treatment with Lusutrombopag +recombinant human thrombopoietin on Day 1, and study treatment will continue for 7 days
Study NCT06675760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The intervention group
Description: The intervention group received training through a mobile augmented reality application in the laboratory.
Study NCT05788991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dequalinium Chloride
Description: Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days
Study NCT05788991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: Metronidazole oral tablets (500 mg) taken twice a day for 7 days
Study NCT06607770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karelizumab+Apatinib
Description: Karelizumab 200mg, q3w, and Apatinib 250mg, qd. every 3 weeks as a treatment cycle.
Study NCT06750549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENGAGE-HF Mobile Application
Description: The mobile app aids ambulatory heart failure monitoring and patient engagement through several features:~Physiologic Monitoring: Daily tracking of blood pressure, weight, and heart rate using Bluetooth devices. Data is shown in graphical and tabular formats.~Health Status Assessment: Biweekly KCCQ-12 surveys and dizziness questions provide scores (0-100), helping visualize therapy benefits and medication adherence, and reducing clinician inertia.~Medication Checklist: Lists current medications and target doses for common heart failure therapies, encouraging adherence and optimization, with alerts for potential improvements.~Education: Animated videos from heart failure experts and societies explain medications, monitoring rationale, app features, and interpretation of data.~The app enhances heart failure management via consistent monitoring, assessment, medication adherence, and educational content.
Study NCT05896839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney Biopsy
Description: Undergo kidney biopsy
Study NCT05896839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05896839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05896839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT05896839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT05575063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Investigational Healon Endocoat
Description: Ophthalmic Viscoelastic device
Study NCT05575063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Healon Endocoat
Description: Ophthalmic Viscoelastic device
Study NCT06489431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
Study NCT06489431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Aminoglycoside antibiotic irrigation
Study NCT06489431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Antibacterial known to inhibit DNA-dependent RNA polymerase
Study NCT05301764 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LVGN6051 and Anlotinib
Description: LVGN6051: Route of administration is IV infusion, and the frequency of administration is once every 3 weeks(Q3W). One cycle is 3 weeks, and treatment can be up to 35 cycles if patients receive benefits. Anlotinib: Rout of administration is oral. The initial dose of anlotinib was 12 mg for subjects with body surface area ≥ 1.5m2 and 10 mg for subjects with body surface area \< 1.5m2. If the subjects in the combined treatment group were not tolerated, the dose of anlotinib was reduced to 10 mg for subjects with body surface area ≥ 1.5m2 and 8 mg for subjects with body surface area \< 1.5m2.~One cycle is 3 weeks, including oral for 2 weeks and withdrawal for 1 week.
Study NCT06116175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 degree thermal radiofequency of tennis elbow
Description: under strict aseptic technique ultrasound guided TRF of lateral epicondylitis advanced for 5 mm active tip canula
Study NCT06264830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alcon-NGENUITY®(NG)-system
Description: During operation, the Alcon NGENUITY® (NG) System is mounted on microscope, while the surgeon will wear 3D glasses, watch 3D screen, and perform operation
Study NCT06264830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard cataract operation
Description: Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
Study NCT06264830 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cataract operation
Description: Standard, modern cataract extraction with standard phacoemulsification technique, and posterior chamber intraocular lens implantation.
Study NCT05575063 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Healon EndoCoat
Description: Ophthalmic Viscoelastic device